Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | BRAF V600E PTEN del |
Therapy | Cobimetinib + Vemurafenib |
Indication/Tumor Type | melanoma |
Response Type | decreased response |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E PTEN del | melanoma | decreased response | Cobimetinib + Vemurafenib | Preclinical - Cell culture | Actionable | In a preclinical study, a melanoma cell line harboring BRAF V600E and engineered via CRISPR-Cas9 to harbor a PTEN knockout demonstrated decreased sensitivity to treatment with Cotellic (cobimetinib) and Zelboraf (vemurafenib) compared to cells with wild-type PTEN in culture (PMID: 38854737). | 38854737 |
PubMed Id | Reference Title | Details |
---|---|---|
(38854737) | Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of PTEN-null, BRAFV600E melanoma to BRAF/MEK inhibition. | Full reference... |